In a filing, Editas Medicine Inc revealed its SVP, Chief Financial Officer Parison Amy unloaded Company’s shares for reported $769.0 on Jun 03 ’25. In the deal valued at $1.72 per share,446 shares were sold. As a result of this transaction, Parison Amy now holds 17,506 shares worth roughly $37812.96.
Then, Burkly Linda sold 726 shares, generating $1,252 in total proceeds. Upon selling the shares at $1.72, the EVP, CHIEF SCIENTIFIC OFFICER now owns 69,519 shares.
Before that, O’Neill Gilmore Neil sold 15,192 shares. Editas Medicine Inc shares valued at $26,196 were divested by the CEO at a price of $1.72 per share. As a result of the transaction, O’Neill Gilmore Neil now holds 280,282 shares, worth roughly $0.61 million.
H.C. Wainwright initiated its Editas Medicine Inc [EDIT] rating to a Buy in a research note published on April 28, 2025; the price target was $3. A number of analysts have revised their coverage, including JP Morgan’s analysts, who decreased its forecast for the stock in mid December from “a Neutral” to “an Underweight”. Truist also remained covering EDIT and has decreased its forecast on December 13, 2024 with a “Hold” recommendation from previously “Buy” rating. Stifel revised its rating on December 13, 2024. It rated EDIT as “a Hold” which previously was an “a Buy”.
Price Performance Review of EDIT
On Monday, Editas Medicine Inc [NASDAQ:EDIT] saw its stock jump 9.64% to $2.16. Over the last five days, the stock has gained 11.92%. Editas Medicine Inc shares have risen nearly 70.08% since the year began. Nevertheless, the stocks have fallen -64.24% over the past one year. While a 52-week high of $6.05 was reached on 02/19/25, a 52-week low of $0.91 was recorded on 04/07/25.
Levels Of Support And Resistance For EDIT Stock
The 24-hour chart illustrates a support level at 2.0000, which if violated will result in even more drops to 1.8300. On the upside, there is a resistance level at 2.2600. A further resistance level may holdings at 2.3600.
